FDA and CDC Suppressed Vaccine Efficacy Studies, Documents Show

The Department of Health and Human Services confirmed that the Food and Drug Administration prevented the release of two agency‑authored studies on COVID‑19 and shingles vaccines. At the same time, the Centers for Disease Control and Prevention halted a peer‑reviewed investigation that had quantified a sharp drop in emergency‑room visits and hospital stays among vaccinated, healthy adults.

The FDA manuscript, prepared by agency scientists, concluded that “the benefits of vaccination outweigh the risks” based on the evidence available. The study, an observational cohort analysis of tens of thousands of vaccine recipients, compared rates of severe outcomes with an unvaccinated control group. The CDC study, a retrospective cohort of over 200,000 adults, found a 70% reduction in emergency care and a 65% cut in hospitalization risk for those who received a COVID‑19 shot.

Both studies passed internal scientific vetting but were ordered withdrawn by unnamed officials. One abstract remains on a conference website, but the full paper was never published in a medical journal. The CDC’s cancellation came after the acting director raised methodological concerns, despite the study’s use of standard statistical controls and a clear temporal link between vaccination and outcome reduction.

These actions contrast with Health Secretary Robert F. Kennedy’s public pledge for “radical transparency.” The suppression of data that supports vaccine benefits limits public access to information that could inform personal health decisions.

What It Means The blocked studies provide quantitative evidence that COVID‑19 vaccines significantly lower the likelihood of severe disease requiring emergency care or hospitalization. For individuals weighing vaccination, the data suggest a measurable protective effect, not merely a correlation. Health providers can cite these findings when discussing vaccine benefits with patients.

The episode underscores the importance of independent peer review and open data. Stakeholders should monitor forthcoming Freedom of Information Act requests and any legal challenges that may compel the agencies to release the full manuscripts. Future transparency will be a key metric for assessing the agencies’ compliance with the administration’s stated openness.